Turbine, a biotech company specializing in AI-driven cell simulations, has announced a research collaboration with Merck & Co., Inc., Rahway, N.J., USA, to simulate cancer patient populations that are difficult to study in laboratory settings. Using Turbine’s proprietary Simulated Cells™, the partnership aims to uncover novel dependencies in highly resistant tumor types, guiding experimental efforts from Merck & Co., Inc., Rahway, N.J., USA, to validate novel drug targets, biomarkers and rational combination therapies. The initial one-year agreement includes an option for Merck & Co., Inc., Rahway, N.J., USA, to extend access to Turbine’s virtual lab and tumor models.
